Literature DB >> 17156859

Antibody induction of lupus-like neuropsychiatric manifestations.

David A Lawrence1, Valerie J Bolivar, Chad A Hudson, Tapan K Mondal, Nina G Pabello.   

Abstract

Although systemic lupus erythematosus (SLE) is usually evaluated with regard to autoimmune reactivity toward the kidney, there are multiple psychiatric abnormalities associated with this autoimmune disease. Lupus-prone male NZM88 mice, derived from NZB/NZW F1 mice, develop early neuropsychiatric manifestations without any signs of nephritis. In addition to the usual repertoire of antibody specificities, including autoantibodies to dsDNA and renal antigens, mice of this inbred strain express autoantibodies to numerous brain antigens. Here, we show that autoantibodies to brain antigens, assessed by Western analysis, are as individually varied as are the diverse neuropsychiatric manifestations observed in SLE patients. Additionally, a monoclonal antibody derived from the spleen of an untreated NZM88 male when injected into healthy BALB/cByJ, but not C57BL/6J, mice induced behaviors similar to those of lupus-prone NZM88 mice. This monoclonal antibody, which is specific to dynamin-1, binds preferentially in BALB/cByJ cortex and induces substantial expression of cytokines mainly in the hypothalamus. Thus, an antibody to just one brain antigen can induce multiple behavioral changes, and multiple autoantibodies to different brain antigens exist in lupus-prone mice; however, susceptibility to the induction of neurobehavioral deficits is dependent on host genetics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17156859      PMCID: PMC1847384          DOI: 10.1016/j.jneuroim.2006.10.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  35 in total

Review 1.  Evaluation of patients with CNS involvement in SLE.

Authors:  J G Hanly
Journal:  Baillieres Clin Rheumatol       Date:  1998-08

2.  Thigmotaxis as a test for anxiolytic activity in rats.

Authors:  D Treit; M Fundytus
Journal:  Pharmacol Biochem Behav       Date:  1988-12       Impact factor: 3.533

3.  The incidence and prognosis of central nervous system disease in systemic lupus erythematosus.

Authors:  J T Sibley; W P Olszynski; W E Decoteau; M B Sundaram
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

Review 4.  Neurology of systemic autoimmune disorders: a pediatric perspective.

Authors:  N F Schor
Journal:  Semin Pediatr Neurol       Date:  2000-06       Impact factor: 1.636

5.  Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

Authors:  R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

6.  The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; John R Brandt; Courtney R Johnson; Marcos E Maldonado; Samir R Patel; Corey C Ford; Arthur D Bankhurst; William M Brooks
Journal:  J Rheumatol       Date:  2002-07       Impact factor: 4.666

7.  Activation of dynamin GTPase by acidic phospholipids and endogenous rat brain vesicles.

Authors:  P L Tuma; M C Stachniak; C A Collins
Journal:  J Biol Chem       Date:  1993-08-15       Impact factor: 5.157

8.  Clinical neurology and brain histopathology in NZB/NZW F1 lupus mice.

Authors:  A B Kier
Journal:  J Comp Pathol       Date:  1990-02       Impact factor: 1.311

9.  Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  H G Bluestein; G W Williams; A D Steinberg
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

Review 10.  New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects.

Authors:  U H Rudofsky; D A Lawrence
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

View more
  7 in total

1.  Induction of autoimmunity to brain antigens by developmental mercury exposure.

Authors:  Yubin Zhang; Donghong Gao; Valerie J Bolivar; David A Lawrence
Journal:  Toxicol Sci       Date:  2010-11-11       Impact factor: 4.849

2.  Detection of immunoglobulin isotypes from dried blood spots.

Authors:  Nancy J Andersen; Tapan Kumar Mondal; Mark T Preissler; Brian M Freed; Sabine Stockinger; Erin Bell; Charlotte Druschel; Germaine M Buck Louis; David A Lawrence
Journal:  J Immunol Methods       Date:  2013-12-13       Impact factor: 2.303

3.  Anti-alpha-internexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis.

Authors:  Xiao-ye Lu; Xiao-xiang Chen; Li-dong Huang; Chang-qing Zhu; Yue-ying Gu; Shuang Ye
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

4.  Depression is an early disease manifestation in lupus-prone MRL/lpr mice.

Authors:  Hua-Xin Gao; Sean R Campbell; Min-Hui Cui; Pu Zong; Jong Hee-Hwang; Maria Gulinello; Chaim Putterman
Journal:  J Neuroimmunol       Date:  2009-01-03       Impact factor: 3.478

5.  Circulating brain-reactive autoantibodies and behavioral deficits in the MRL model of CNS lupus.

Authors:  S Williams; B Sakic; S A Hoffman
Journal:  J Neuroimmunol       Date:  2009-11-17       Impact factor: 3.478

6.  Diagnosis and early detection of CNS-SLE in MRL/lpr mice using peptide microarrays.

Authors:  Stephanie Williams; Phillip Stafford; Steven A Hoffman
Journal:  BMC Immunol       Date:  2014-06-07       Impact factor: 3.615

7.  Correlation between physical markers and psychiatric health in a Portuguese systemic lupus erythematosus cohort: The role of suffering in chronic autoimmune disease.

Authors:  Margarida Figueiredo-Braga; Caleb Cornaby; Miguel Bernardes; Marta Figueiredo; Cristina Dos Santos Mesquita; Lúcia Costa; Brian D Poole
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.